search.noResults

search.searching

saml.title
dataCollection.invalidEmail
note.createNoteMessage

search.noResults

search.searching

orderForm.title

orderForm.productCode
orderForm.description
orderForm.quantity
orderForm.itemPrice
orderForm.price
orderForm.totalPrice
orderForm.deliveryDetails.billingAddress
orderForm.deliveryDetails.deliveryAddress
orderForm.noItems
Women’s health


Tackling inequalities in cardiovascular research


Mark Campbell looks at why women remain under-represented in cardiometabolic clinical studies and argues that we need to move beyond awareness to infrastructure.


Despite decades of recognition, women remain systematically under-represented in clinical research, particularly in cardiovascular and cardiometabolic studies. This imbalance has been consistently documented across studies of coronary artery disease, heart failure and cardiometabolic conditions, where women often account for only a third of participants, despite representing a substantial proportion of the disease population.1 The implications are significant; under-


representation limits the ability to detect sex-specific differences in treatment response, safety and dosing, and constrains the generalisability of findings to representative populations. As highlighted by the Lancet Commission on Women and Cardiovascular Disease, women with cardiovascular disease remain “understudied, under-recognised, underdiagnosed and undertreated”.1 Yet, despite increasing awareness, regulatory


attention and policy initiatives, progress in improving representation has been inconsistent. Participation-to-prevalence ratios continue to demonstrate significant gaps, and in some analyses, representation has not improved over time.2,3


If awareness alone were sufficient, this


problem would have been solved. This persistence suggests that the issue is not solely one of awareness or intent. Instead, it raises a more fundamental question: whether the way clinical studies are designed and delivered continues to shape who can participate. The challenge is particularly relevant in


cardiometabolic research. These conditions are long-term, behaviourally influenced and deeply embedded in everyday life. Management often involves sustained interaction with healthcare systems, lifestyle modification and ongoing monitoring. Participation in clinical studies for these conditions is therefore not a discrete event, but an extension of an individual’s broader health journey. For many individuals, participation in clinical studies must be balanced alongside work, caregiving responsibilities and ongoing health commitments. These factors are not evenly distributed across populations and can disproportionately affect those managing multiple roles and constraints.4 The practical realities of study participation,


including visit frequency, travel requirements, time burden and continuity of engagement, become central determinants of whether


participation is feasible. As a result, the alignment between study design and daily life is not a peripheral issue. It may be a critical factor in determining who ultimately takes part.


The limits of traditional recruitment models Many clinical studies continue to rely on recruitment models that are episodic, site- based and time-bound. Participants are typically identified through healthcare settings, contacted within a defined recruitment window and asked to enrol into a study with specific protocol requirements. While these models have supported significant scientific advances, they are not neutral in their impact. They assume that potential participants can: l Be available at the point of recruitment l Be able to travel to research sites l Be able to accommodate study visits within existing commitments


l Be sufficiently informed and motivated at a single point in time


In practice, these assumptions do not hold uniformly across populations. In effect, study participation is being designed around the system rather than the participant. Evidence has consistently shown that barriers to study participation include logistical constraints, time burden, transport challenges, awareness, and eligibility criteria.4,5


These factors are not simply


individual preferences; they are structural features of how studies are organised. Therefore, access to clinical research is shaped not only by disease prevalence or clinical need, but by how well trial participation fits within the realities of people’s lives. Clinical eligibility alone does not make somebody research-ready. People also need to be informed, engaged and practically able to accommodate participation within their lives.


Why women may be disproportionately affected These structural dynamics may disproportionately affect women. A substantial


52 www.clinicalservicesjournal.com I November 2026


BuyOutFelix02/peopleimages.com - stock.adobe.com


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71